- Home
- LFST vs TARS Comparison
LFST vs TARS Comparison
Compare LFST & TARS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LFST
- TARS
- Stock Information
- Founded
- LFST 2015
- TARS 2016
- Country
- LFST United States
- TARS United States
- Employees
- LFST N/A
- TARS N/A
- Industry
- LFST Medical/Nursing Services
- TARS Medicinal Chemicals and Botanical Products
- Sector
- LFST Health Care
- TARS Health Care
- Exchange
- LFST Nasdaq
- TARS Nasdaq
- Market Cap
- LFST 2.1B
- TARS 1.7B
- IPO Year
- LFST 2021
- TARS 2020
- Fundamental
- Price
- LFST $5.64
- TARS $69.75
- Analyst Decision
- LFST Strong Buy
- TARS Strong Buy
- Analyst Count
- LFST 5
- TARS 7
- Target Price
- LFST $8.60
- TARS $67.14
- AVG Volume (30 Days)
- LFST 1.8M
- TARS 745.5K
- Earning Date
- LFST 11-06-2025
- TARS 11-12-2025
- Dividend Yield
- LFST N/A
- TARS N/A
- EPS Growth
- LFST N/A
- TARS N/A
- EPS
- LFST N/A
- TARS N/A
- Revenue
- LFST $1,316,483,000.00
- TARS $295,521,000.00
- Revenue This Year
- LFST $15.27
- TARS $137.28
- Revenue Next Year
- LFST $14.29
- TARS $42.84
- P/E Ratio
- LFST N/A
- TARS N/A
- Revenue Growth
- LFST 13.86
- TARS 254.45
- 52 Week Low
- LFST $3.74
- TARS $33.16
- 52 Week High
- LFST $8.61
- TARS $70.58
- Technical
- Relative Strength Index (RSI)
- LFST 55.96
- TARS 76.11
- Support Level
- LFST $5.27
- TARS $56.25
- Resistance Level
- LFST $5.72
- TARS $69.47
- Average True Range (ATR)
- LFST 0.18
- TARS 2.43
- MACD
- LFST -0.00
- TARS 1.22
- Stochastic Oscillator
- LFST 60.91
- TARS 95.71
About LFST LifeStance Health Group Inc.
LifeStance Health Group Inc is a mental healthcare company that operates as a provider of outpatient mental health services, spanning psychiatric evaluations and treatment, psychological and neuropsychological testing, and individual, family and group therapy. The group y has a single operating and reportable segment of mental health services.
About TARS Tarsus Pharmaceuticals Inc.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis.